Close Menu

NEW YORK (GenomeWeb News) – Activiomics announced recently a research deal with Kyowa Hakko Kirin for use of Activiomics' mass spectrometry-based technology to "elucidate signaling mechanism of lead compounds in relevant cell-based systems."

Under the deal, the Japanese pharmaceutical firm will use Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology to identify important biomarkers that can be used in the drug-discovery process.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.